AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended ant ...

together with the upfront payments under the agreement with AbbVie, will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2026. Investor ...

"AbbVie is committed to expanding our R&D efforts in oncology ... Xilio explicitly disclaims any obligation to update any forward-looking statements. Vice President, Investor Relations and Corporate ...

AbbVie's combination antibiotic Emblaveo has gotten federal approval to treat complicated intra-abdominal infections, making it the first and only such therapy approved to fight antimicrobial ...

AbbVie (ABBV) has been one of the most searched ... A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher.